Akoya Biosciences Inc

NASDAQ AKYA

Download Data

Akoya Biosciences Inc Enterprise Value to Sales (EV/S) on June 03, 2024: 1.26

Akoya Biosciences Inc Enterprise Value to Sales (EV/S) is 1.26 on June 03, 2024, a -53.83% change year over year. The EV/Sales ratio, also known as the revenue multiple, compares a company's enterprise value to its revenue. It provides insight into the company's valuation relative to its sales and is commonly used in valuation analysis. A lower ratio suggests a potentially more favorable valuation.
  • Akoya Biosciences Inc 52-week high Enterprise Value to Sales (EV/S) is 4.12 on June 15, 2023, which is 226.46% above the current Enterprise Value to Sales (EV/S).
  • Akoya Biosciences Inc 52-week low Enterprise Value to Sales (EV/S) is 1.21 on May 23, 2024, which is -4.18% below the current Enterprise Value to Sales (EV/S).
  • Akoya Biosciences Inc average Enterprise Value to Sales (EV/S) for the last 52 weeks is 2.29.
NASDAQ: AKYA

Akoya Biosciences Inc

CEO Mr. Brian McKelligon
IPO Date April 16, 2021
Location United States
Headquarters 100 Campus Drive, Marlborough, MA, United States, 01752
Employees 330
Sector Healthcare
Industry Medical instruments & supplies
Description

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Similar companies

ANGO

AngioDynamics Inc

NA

NA

PDEX

Pro-Dex Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email